Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Business Revamp “Just Getting Started”: Sumitomo Pharma CEO
August 19, 2024
- Tremfya Filed for Crohn’s Disease in Japan: J&J
August 13, 2024
- MSD Seeks Japan Nod for 21-Valent Pneumococcal Jab for Adults
August 13, 2024
- Opdivo-Yervoy Combo Filed for HCC in Japan
August 13, 2024
- Takeda Seeks CIDP Nod for Immunoglobulin Hyqvia in Japan
August 9, 2024
- Japan Patented Drug Market Breaks 7 Trillion Yen in FY2023: IQVIA
August 9, 2024
- Hizentra Now Available in Prefilled Syringe Form in Japan: CSL
August 9, 2024
- Nobelpharma to Launch Hypozincemia Drug Zintus on August 20
August 9, 2024
- Pfizer Earns Japan Nod for JN.1-Adapted COVID Vaccine
August 9, 2024
- Takeda’s Adzynma Approved in Europe, Launch Set for September
August 9, 2024
- Japan Ethical Drug Sales Down 5.5% in June: Crecon
August 9, 2024
- Daiichi, Merck Expand ADC Deal into Harpoon’s T-Cell Engager
August 8, 2024
- Chugai Gets Japan Rights to Roche’s Anti-TL1A IBD Drug
August 8, 2024
- Anapeine Restriction Forcing Sandoz to Curb Supply of More Local Anesthetics
August 7, 2024
- Sandoz to Discontinue Paxil AGs as Originator Pulls Out
August 7, 2024
- Kyorin, Jikei Startup Ink Option Deal for Respiratory Disease Treatment
August 7, 2024
- NCC Offshoot’s 1st CAR-T Therapy Set to Enter Clinic Next Year: CEO
August 7, 2024
- Santen Axes Diquas LX Outlook to Zero for Now as Supply Halt Continues
August 7, 2024
- Santen Snags Asian Rights to Cloudbreak’s Topical Pterygium Drug
August 7, 2024
- Keytruda Tops Japan Sales Ranking for 10th Straight Month: Encise
August 7, 2024
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…